Adc Thera
web2ADC Therapeutics develops and commercializes antibody-drug conjugate medicines for patients wit...
About
ADC Therapeutics develops and commercializes antibody-drug conjugate medicines for patients with blood cancers, including its marketed treatment for relapsed or refractory large B-cell lymphoma. Its principal commercial product is ZYNLONTA, a CD19-directed therapy used after at least two prior lines of systemic treatment for eligible adults. The company also studies combinations and potential label expansions in clinical trials, including research in earlier treatment settings and other lymphomas. ADC Therapeutics SA is incorporated in Switzerland and has subsidiaries in the United States and United Kingdom. Its common shares trade on the New York Stock Exchange under the symbol ADCT.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Adc Thera profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy